Literature DB >> 3052064

A controlled trial of stimulant medication in children with the fragile X syndrome.

R J Hagerman1, M A Murphy, M D Wittenberger.   

Abstract

Attentional deficits and hyperactivity frequently are major problems for fra(X) boys. This study evaluated the effectiveness of 2 stimulant medications, methylphenidate and dextroamphetamine compared to placebo in 15 children (13 males, 2 females) with the fra(X) syndrome. A double-blind crossover design was used with outcome measures which included parent and teacher behavior checklists, a controlled observation period, continuous performance tasks and an actometer measure of movement. When the children were treated with methylphenidate only, improvement was seen in socialization skills and attention span according to teacher checklists. Ten children were clinically considered responders and treatment was continued after the study was completed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052064     DOI: 10.1002/ajmg.1320300138

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  28 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

2.  FRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIES.

Authors:  Paula M Wadell; Randi J Hagerman; David R Hessl
Journal:  Curr Psychiatry Rev       Date:  2013-02-01

Review 3.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

4.  Outcome measures for clinical trials in fragile X syndrome.

Authors:  Elizabeth Berry-Kravis; David Hessl; Leonard Abbeduto; Allan L Reiss; Andrea Beckel-Mitchener; Tiina K Urv
Journal:  J Dev Behav Pediatr       Date:  2013-09       Impact factor: 2.225

5.  Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective.

Authors:  D J Safer
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 6.  Treatments for fragile X syndrome: a closer look at the data.

Authors:  Scott S Hall
Journal:  Dev Disabil Res Rev       Date:  2009

7.  Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring.

Authors:  Bojana Zupan; Miklos Toth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

Review 8.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  A rational approach to the child with mental retardation for the paediatrician.

Authors:  Jean-François Lemay; Anthony R Herbert; Deborah M Dewey; A Micheil Innes
Journal:  Paediatr Child Health       Date:  2003-07       Impact factor: 2.253

Review 10.  Systematic review of pharmacological treatments in fragile X syndrome.

Authors:  Jose-Ramon Rueda; Javier Ballesteros; Maria-Isabel Tejada
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.